webinar register page

INmune Bio Webinar on Improvements in Multiple Biomarkers of White Matter Pathology, Including a Reduction in Phospho-Tau in Alzheimer’s Disease
INmune Bio will present new data from the Phase Ib trial in patients with Alzheimer’s disease. The Company will present data on XPro™ treatment showing statistically significantly decreases in Phospho Tau 217 (pT271) and pT181, and an improvement in imaging biomarkers of myelination along with expanded biomarker results in patients treated XPro1595 for at least 12 weeks.


* Required information